39 related articles for article (PubMed ID: 3855382)
1. Efficient and Consistent Orthotopic Osteosarcoma Model by Cell Sheet Transplantation in the Nude Mice for Drug Testing.
Wu H; He Z; Li X; Xu X; Zhong W; Bu J; Huang G
Front Bioeng Biotechnol; 2021; 9():690409. PubMed ID: 34631675
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective.
Benjamin RS
Adv Exp Med Biol; 2020; 1257():1-10. PubMed ID: 32483726
[TBL] [Abstract][Full Text] [Related]
3. Single-Center Experience with Ifosfamide Monotherapy as Second-Line Treatment of Recurrent/Metastatic Osteosarcoma.
Verschoor AJ; Speetjens FM; Dijkstra PDS; Fiocco M; van de Sande MAJ; Bovée JVMG; Gelderblom H
Oncologist; 2020 Apr; 25(4):e716-e721. PubMed ID: 32297446
[TBL] [Abstract][Full Text] [Related]
4. Treatment pathway of bone sarcoma in children, adolescents, and young adults.
Reed DR; Hayashi M; Wagner L; Binitie O; Steppan DA; Brohl AS; Shinohara ET; Bridge JA; Loeb DM; Borinstein SC; Isakoff MS
Cancer; 2017 Jun; 123(12):2206-2218. PubMed ID: 28323337
[TBL] [Abstract][Full Text] [Related]
5. STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma.
Oi T; Asanuma K; Matsumine A; Matsubara T; Nakamura T; Iino T; Asanuma Y; Goto M; Okuno K; Kakimoto T; Yada Y; Sudo A
Int J Oncol; 2016 Dec; 49(6):2275-2284. PubMed ID: 27840900
[TBL] [Abstract][Full Text] [Related]
6. The Current and Future Therapies for Human Osteosarcoma.
Lamplot JD; Denduluri S; Qin J; Li R; Liu X; Zhang H; Chen X; Wang N; Pratt A; Shui W; Luo X; Nan G; Deng ZL; Luo J; Haydon RC; He TC; Luu HH
Curr Cancer Ther Rev; 2013 Feb; 9(1):55-77. PubMed ID: 26834515
[TBL] [Abstract][Full Text] [Related]
7. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.
Isakoff MS; Bielack SS; Meltzer P; Gorlick R
J Clin Oncol; 2015 Sep; 33(27):3029-35. PubMed ID: 26304877
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials.
Su W; Lai Z; Wu F; Lin Y; Mo Y; Yang Z; Wu J
Med Oncol; 2015 Feb; 32(2):481. PubMed ID: 25575440
[TBL] [Abstract][Full Text] [Related]
9. The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.
Xiao X; Wang W; Wang Z
Paediatr Drugs; 2014 Dec; 16(6):503-12. PubMed ID: 25392156
[TBL] [Abstract][Full Text] [Related]
10. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma.
Meyers PA; Healey JH; Chou AJ; Wexler LH; Merola PR; Morris CD; Laquaglia MP; Kellick MG; Abramson SJ; Gorlick R
Cancer; 2011 Apr; 117(8):1736-44. PubMed ID: 21472721
[TBL] [Abstract][Full Text] [Related]
11. The multidisciplinary management of osteosarcoma.
Federman N; Bernthal N; Eilber FC; Tap WD
Curr Treat Options Oncol; 2009 Apr; 10(1-2):82-93. PubMed ID: 19238553
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma.
Michelagnoli MP; Lewis IJ; Gattamaneni HR; Bailey CC; Lashford LS
Br J Cancer; 1999 Mar; 79(7-8):1174-8. PubMed ID: 10098754
[TBL] [Abstract][Full Text] [Related]
13. Comparative activity of ifosfamide and cyclophosphamide.
Brade W; Seeber S; Herdrich K
Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S1-9. PubMed ID: 3545522
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide in pediatric malignant solid tumors.
Pratt CB; Douglass EC; Etcubanas EL; Goren MP; Green AA; Hayes FA; Horowitz ME; Meyer WH; Thompson EI; Wilimas JA
Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S24-7. PubMed ID: 2503257
[TBL] [Abstract][Full Text] [Related]
15. Nephrotoxicity after ifosfamide.
Skinner R; Pearson AD; Price L; Coulthard MG; Craft AW
Arch Dis Child; 1990 Jul; 65(7):732-8. PubMed ID: 2386379
[TBL] [Abstract][Full Text] [Related]
16. High-dose ifosfamide in advanced osteosarcoma.
Marti C; Kroner T; Remagen W; Berchtold W; Cserhati M; Varini M
Cancer Treat Rep; 1985 Jan; 69(1):115-7. PubMed ID: 3855382
[TBL] [Abstract][Full Text] [Related]
17. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of ifosfamide in children with malignant solid tumors.
Pratt CB; Horowitz ME; Meyer WH; Etcubanas E; Thompson EI; Douglass EC; Wilimas JA; Hayes FA; Green AA
Cancer Treat Rep; 1987 Feb; 71(2):131-5. PubMed ID: 3100034
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy of the non-small cell carcinoma of the lung with ifosfamide and cisplatin].
Drings P; Stiefel P; Dirks HP; Grimm V; Kleckow M; Manke HG; Queisser W; Abel U; Heinrich S
Dtsch Med Wochenschr; 1984 Jul; 109(27):1059-64. PubMed ID: 6086264
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
